state board — 3 things I got wrong before I got it right
The title is the argument: state board — 3 things I got wrong before I got it right. Here is the rest of it.
Nothing in this thread is medical advice, and the choice between arrangements is one for you and a prescriber who knows your history.
Potency and sterility testing on the finished preparation are separate from any certificate covering the starting material. Ask which you are being shown.
Salt form matters for mass: a preparation specified as one salt and dosed as the free base gives you a different amount of peptide for the same number on the label.
Ask me anything specific. Anything general I will probably get wrong.
best — the order this archive was captured in
A 503A pharmacy compounds for an identified patient against a prescription. A 503B outsourcing facility registers with the regulator, may produce without patient-specific prescriptions, and is subject to current good manufacturing practice requirements. The two are governed differently and the difference is not cosmetic.
Is the compound still on the shortage list where you are?
What concentration is on the label, and does it match what you were expecting?
salt forms are the recurring argument and the answer is boring
salt forms are the recurring argument and the answer is boring
Adding one thing — ask for the facility name. Most will give it, and the ones that will not have answered you.
Right, and the concentration genuinely can differ from the branded product, which breaks people’s arithmetic.
A beyond-use date derived from published stability data means something different from one assigned by default rule. Asking which is a fair question and the answer is usually available.
Yes. The shortage list is the legal hinge for the whole arrangement and its status is public.
potency testing on the finished preparation is the thing to ask for
the label on a compounded vial is a legal document, read it
the label on a compounded vial is a legal document, read it
Disagreeing with this bit: registration is not equivalence, and the two get run together constantly.
This. Compounded preparations carry no equivalence claim, and treating them as generics is a category error people make constantly.
Concentration on the compounded vial was different from what I had been using and I nearly did the arithmetic on autopilot.
The shortage list is the legal hinge: the permissions that allow certain compounding to happen at scale are tied to a drug’s shortage status, which changes.
compounded is not generic, there is no equivalence claim
Agreed. The 503A versus 503B distinction changes who is allowed to make what, and almost every confused thread here starts by ignoring it.
I would not read the price difference as a quality signal. Most of it is the consultation model, not the vial.
Switched between two compounded preparations and the concentration on the label was different. Redid the arithmetic on paper before drawing anything.
The five questions worth asking before you commit to any compounded arrangement.
Which facility, by name. Whether it is a 503A pharmacy or a 503B outsourcing facility. What concentration is on the label. What the beyond-use date is based on. Whether there is potency testing on the finished preparation rather than only on the starting material.
All five are answerable in one email and the pattern of what comes back is more informative than any of the individual answers. An organisation with a quality system finds these questions ordinary.
What is the beyond-use date and what is it based on?
What did the intake actually ask you?
That figure is the starting material purity, not the finished preparation potency. Two different tests.
the shortage list is the whole legal hinge and people skip it
Correction: patient-specific refers to the prescription, not to a bespoke formulation. Common misreading and it changes the argument.
- 1salt forms are the recurring argument and the answer is boring9 comments in this branch · started by u/stubborn_batchlist_pls